Pharmaceuticals News

Regeneron is renewing it's sponsorship of the Science Talent Search for the next 10 years, committing $150 million.

Nantes, le 26 février 2026 – 18h00 CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo : OSE) annonce aujourd’hui que le Comité Indépendant de Surveillance des Données (IDMC) a émis une...

OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer

Trésorerie et équivalents de trésorerie s’élevant à 101,1 millions d’euros au 31 décembre 2025Revenus s’élevant à 65,4 millions d’euros pour l’exercice 2025Solide performance d’Iqirvo® d’Ipsen dans la...

Cash and cash equivalents totaled €101.1 million as of December 31, 2025Revenues amounted to €65.4 million as of December 31, 2025Ipsen’s strong performance with Iqirvo® in PBC (>$200M net sales in...

Key Takeaways: Regeneron will extend its title sponsorship of the Regeneron Science Talent Search (STS) for a second decade, continuing its partnership with Society for Science to support the United...

Flourish Research partners with Capitol Imaging Services to launch Flourish Imaging featuring GE Omni PET scanner in Gainesville, GA.

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016of 8 March 2016,...

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles BOSTON, Feb. 26, 2026 (GLOBE...

Tevogen evaluates acquisition of Sciometrix to build integrated clinical infrastructure and advance its 2026 revenue goals.